GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

Daiichi Sankyo and Merck Announce Global Development and Commercialization Partnership for MK-6070

NextEdge Admin

07 Aug 2024

1 min 48 sec

Merck,small cell lung cancer,neuroendocrine tumors

Daiichi Sankyo and Merck , known as MSD outside the U.S. and Canada, have expanded their global co-development and co-commercialization agreement to include Merck’s MK-6070, an investigational DLL3-targeting T-cell engager. This partnership excludes Japan, where Merck retains exclusive rights, and Merck will handle all manufacturing and supply for MK-6070.

MK-6070, acquired through Merck’s acquisition of Harpoon Therapeutics, is currently in a Phase 1/2 clinical trial (NCT04471727) targeting DLL3, highly expressed in small cell lung cancer (SCLC) and neuroendocrine tumors. The companies plan to evaluate MK-6070 in combination with ifinatamab deruxtecan (I-DXd) for SCLC and other potential combinations.

Ken Takeshita, MD, global head of R&D at Daiichi Sankyo, stated that this expansion aligns with their strategy to set new cancer care standards. He highlighted the synergy between MK-6070 and their established antibody-drug conjugate collaboration, particularly with I-DXd.

Dr. Dean Y. Li, president of Merck Research Laboratories, emphasized the urgent need for new treatments for aggressive SCLC. He expressed enthusiasm for the expanded collaboration with Daiichi Sankyo and the potential of combining MK-6070 and ifinatamab deruxtecan in treating SCLC and other cancers.